semaglutide and bowel obstruction Can a patient who developed a while on a GLP‑1 receptor agonist (e.g., exenatide, liraglutide, semaglutide, dulaglutide) safely continue the GLP‑1 therapy? michigan semaglutide bowel obstruction legal

Intervention Seventy eligible participants were randomly assigned (1:1) to either semaglutide 2.4 mg weekly (Novo Nordisk) ( n = 35) or placebo (saline solution) ( n = 35), using self-administered once-weekly subcutaneous injections with identical-appearing pens

Weight regain risk is highest in the first 3 to 6 months after stopping, with some patients reporting 30-50% of lost weight returning during this window

This can reduce inflammation in the body, which is a contributing factor to certain types of anemia, such as anemia of chronic disease

Exosome treatments have not been approved by the FDA for any therapeutic use in humans

At Primary Care El Paso, patients receive personalized evaluations and treatment plans designed to support sustainable weight loss and overall wellness

Astrup A, Carraro R, Harper A, et al